BR112017004796A2 - método para utilizar derivados de ácido hidroxâmico e substância antibacterial em combinação - Google Patents

método para utilizar derivados de ácido hidroxâmico e substância antibacterial em combinação

Info

Publication number
BR112017004796A2
BR112017004796A2 BR112017004796A BR112017004796A BR112017004796A2 BR 112017004796 A2 BR112017004796 A2 BR 112017004796A2 BR 112017004796 A BR112017004796 A BR 112017004796A BR 112017004796 A BR112017004796 A BR 112017004796A BR 112017004796 A2 BR112017004796 A2 BR 112017004796A2
Authority
BR
Brazil
Prior art keywords
hydroxamic acid
hydroxy
combination
acid derivatives
antibacterial substance
Prior art date
Application number
BR112017004796A
Other languages
English (en)
Inventor
Nakagawa Akiko
Eto Maki
Fujiwara Masasuke
Funatsu Tori
Original Assignee
Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyama Chemical Co Ltd filed Critical Toyama Chemical Co Ltd
Publication of BR112017004796A2 publication Critical patent/BR112017004796A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

são reveladas composições farmacológicas que contêm um derivado de ácido hidroxâmico selecionado a partir de (2s) -2 - ((4 - ((4 - ((1s) -1,2-di-hidroxietil) fenil) etinil) benzoíl) (metil) amino) -n-hidroxi- n', 2-dimetilmalonamida, (2s) -2 - ((4 - ((4 - ((1r) -1,2-di-hidroxietil) fenil) etinil) benzoíl) (metil) amino) -n-hidroxi-n', 2-dimetilmalonamida, e (2s) -n-hidroxi-2 - ((4 - ((4 - ((1s) -1-hidroxi-2-metoxietil) fenil) etinil) benzoíl) (metil) amino) -n', 2-dimetilmalonamida, ou um sal dos referidos derivados, e uma substância antibiótica que são úteis no tratamento de infecções bacterianas gram-negativas.
BR112017004796A 2014-09-12 2015-09-11 método para utilizar derivados de ácido hidroxâmico e substância antibacterial em combinação BR112017004796A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014186569 2014-09-12
PCT/JP2015/075778 WO2016039432A1 (ja) 2014-09-12 2015-09-11 新規なヒドロキサム酸誘導体および抗菌性物質を組み合わせて使用する方法

Publications (1)

Publication Number Publication Date
BR112017004796A2 true BR112017004796A2 (pt) 2017-12-12

Family

ID=55459176

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017004796A BR112017004796A2 (pt) 2014-09-12 2015-09-11 método para utilizar derivados de ácido hidroxâmico e substância antibacterial em combinação

Country Status (14)

Country Link
US (1) US10123990B2 (pt)
EP (1) EP3192505A4 (pt)
JP (1) JPWO2016039432A1 (pt)
KR (1) KR20170047390A (pt)
CN (1) CN106794162A (pt)
AU (1) AU2015316400A1 (pt)
BR (1) BR112017004796A2 (pt)
CA (1) CA2960936A1 (pt)
IL (1) IL250884A0 (pt)
MX (1) MX2017003011A (pt)
RU (1) RU2017112303A (pt)
SG (1) SG11201701955UA (pt)
WO (1) WO2016039432A1 (pt)
ZA (1) ZA201701770B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200308105A1 (en) * 2016-03-31 2020-10-01 Fujifilm Toyama Chemical Co., Ltd. Novel method for producing hydroxamic acid derivative, and intermediate therefor
CN109415302A (zh) * 2016-03-31 2019-03-01 富士胶片富山化学株式会社 新的异羟肟酸衍生物的晶体、其制造方法及医药用组合物
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
CA3077474A1 (en) 2017-10-02 2019-04-11 Arixa Pharmaceuticals, Inc. Aztreonam derivatives and uses thereof
JP7437847B2 (ja) 2018-10-01 2024-02-26 アリクサ ファーマシューティカルズ、インコーポレイテッド レレバクタムの誘導体およびその使用
JP2022524118A (ja) 2019-03-12 2022-04-27 アリクサ ファーマシューティカルズ、インコーポレイテッド アビバクタム誘導体の結晶形
US11565999B2 (en) 2019-04-25 2023-01-31 Arixa Pharmaceuticals, Inc. Methods of synthesizing aztreonam derivatives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101145252B1 (ko) 2003-01-08 2012-05-24 유니버시티 오브 워싱톤 항균제
EP1963262A2 (en) 2005-12-15 2008-09-03 Vicuron Pharmaceuticals, Inc. N-hydroxyamide derivatives possessing antibacterial activity
EP2662353A3 (en) 2007-06-12 2014-04-02 Achaogen, Inc. Antibacterial agents
JP2011529964A (ja) 2008-08-04 2011-12-15 シェーリング コーポレイション 抗菌剤としての尿素誘導体
US8372885B2 (en) 2008-09-17 2013-02-12 Novartis Ag Organic compounds and their uses
CA2735929C (en) 2008-09-19 2013-12-17 Pfizer Inc. Hydroxamic acid derivatives useful as antibacterial agents
TR201908891T4 (tr) * 2010-04-20 2019-07-22 Fujifilm Toyama Chemical Co Ltd Yeni̇ hi̇droksami̇k asi̇t türevi̇
WO2013170165A1 (en) 2012-05-10 2013-11-14 Achaogen, Inc. Antibacterial agents
DK2975022T3 (da) * 2013-03-15 2019-07-15 Fujifilm Toyama Chemical Co Ltd Hidtil ukendt hydroxaminsyrederivat eller salt deraf

Also Published As

Publication number Publication date
SG11201701955UA (en) 2017-04-27
RU2017112303A (ru) 2018-10-12
EP3192505A1 (en) 2017-07-19
CA2960936A1 (en) 2016-03-17
RU2017112303A3 (pt) 2019-04-19
IL250884A0 (en) 2017-04-30
EP3192505A4 (en) 2018-04-25
ZA201701770B (en) 2018-08-29
CN106794162A (zh) 2017-05-31
US20170296503A1 (en) 2017-10-19
MX2017003011A (es) 2017-05-30
US10123990B2 (en) 2018-11-13
WO2016039432A1 (ja) 2016-03-17
JPWO2016039432A1 (ja) 2017-06-22
AU2015316400A1 (en) 2017-04-06
KR20170047390A (ko) 2017-05-04

Similar Documents

Publication Publication Date Title
BR112017004796A2 (pt) método para utilizar derivados de ácido hidroxâmico e substância antibacterial em combinação
BR112018070602A2 (pt) composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio
CY1121701T1 (el) Οργανικες ενωσεις μονοβακταμης για την αντιμετωπιση βακτηριακων λοιμωξεων
DK3331864T3 (da) 1,3,4-Oxadiazolderivat-forbindelser som histon-deacetylase-6-hæmmer, og den farmaceutiske sammensætning omfattende disse
BR112019003504A2 (pt) compostos de amino-pirrolopirimidinona e métodos de uso dos mesmos
BR112017007460A2 (pt) inibidores de di-hidropirrolopiridina de ror-gama
EA201890731A1 (ru) Модуляторы корового белка гепатита b
BR112016028288A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto?
DK3330259T3 (da) 1,3,4-oxadiazolamidderivativ-forbindelse som histondeacetylase-6-inhibitor og farmaceutisk sammensætning indeholdende denne
BR112016015449A8 (pt) compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos
CY1123509T1 (el) Αλατα και στερεες μορφες ενος αντιβιοτικου μονοβακταμης
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
BR112015027704A2 (pt) Composto, uso do mesmo e composição farmacêutica antibacteriana
CY1122805T1 (el) Ενωσεις και μεθοδοι για την αγωγη βακτηριακων λοιμωξεων
BR112012026767A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratar ou previnir distúrbios, e, uso de um composto ou sal
WO2017083431A3 (en) Hydroxypyridinone and hydroxypyrimidinone based compounds for treating bacterial infections
BR112014000665A2 (pt) composto, uso do mesmo, composição farmacêutica, agente antimicrobiano, e, método para previnir ou tratar uma infecção bacteriana
MX2017002967A (es) Composicion farmaceutica novedosa que contiene derivado de acido hidroxamico o sal del mismo.
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
CL2016000568A1 (es) Compuestos derivados de 2h-indazol-2-il-n-hidroxi-2-metilsulfonil-2-metil-butanamida sustituidos o sus sales; sus composiciones farmacéuticas que los contiene y su uso para la prevención y/o tratamiento de infecciones bacterianas gram-negativas.
EA201691600A1 (ru) Дигидропиридиноновые ингибиторы mgat2 для применения в лечении метаболических нарушений
BR112018010255A2 (pt) antibióticos macrocíclicos de amplo espectro
BR112019000453A2 (pt) combinação de ceftibuteno e ácido clavulânico para uso no tratamento de infecções bacterianas
BR112018074985A2 (pt) composições antibacterianas
EA201791530A1 (ru) НОВЫЕ N-АЦИЛАРИЛСУЛЬФОНАМИДНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ АМИНОАЦИЛ-тРНК СИНТЕТАЗЫ

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B25A Requested transfer of rights approved

Owner name: FUJIFILM TOYAMA CHEMICAL CO., LTD. (JP)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2595 DE 29-09-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]